Selecta Biosciences Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Selecta Biosciences stock.
View analyst ratings for Selecta Biosciences or view top-rated stocks.

Wall Street analysts have given Selecta Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Selecta Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Selecta Biosciences saw a increase in short interest in January. As of January 15th, there was short interest totaling 6,120,000 shares, an increase of 13.3% from the December 31st total of 5,400,000 shares. Based on an average trading volume of 2,440,000 shares, the days-to-cover ratio is presently 2.5 days.
View Selecta Biosciences' Short Interest.

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Selecta Biosciences.

Selecta Biosciences, Inc. (NASDAQ:SELB) issued its earnings results on Thursday, August, 6th. The company reported ($0.25) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.32 by $0.57.
View Selecta Biosciences' earnings history.

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SELB shares have increased by 34.0% and is now trading at $4.14.
View which stocks have been most impacted by COVID-19.

7 analysts have issued 1 year target prices for Selecta Biosciences' stock. Their forecasts range from $4.00 to $13.00. On average, they expect Selecta Biosciences' stock price to reach $7.20 in the next twelve months. This suggests a possible upside of 73.9% from the stock's current price.
View analysts' price targets for Selecta Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Selecta Biosciences include ImmunoGen (IMGN), Frequency Therapeutics (FREQ), PMV Pharmaceuticals (PMVP), Heron Therapeutics (HRTX), Arcutis Biotherapeutics (ARQT), Revance Therapeutics (RVNC), Nkarta (NKTX), Antibe Therapeutics (ATBPD), Antibe Therapeutics (ATBPF), Antibe Therapeutics (ATBPD), Shattuck Labs (STTK), uniQure (QURE), Olema Pharmaceuticals (OLMA), Kura Oncology (KURA) and Kronos Bio (KRON).
View all of SELB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Selecta Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.07%), Armistice Capital LLC (1.51%), Morgan Stanley (1.22%), JPMorgan Chase & Co. (0.92%), Endurant Capital Management LP (0.92%) and Renaissance Technologies LLC (0.90%). Company insiders that own Selecta Biosciences stock include Carsten Brunn, Peter G Traber, Timothy A Springer and Timothy C Barabe.
View institutional ownership trends for Selecta Biosciences.

SELB stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Endurant Capital Management LP, Alliancebernstein L.P., Wells Fargo & Company MN, New York State Common Retirement Fund, Virtus ETF Advisers LLC, Barclays PLC, and Northern Trust Corp.
View insider buying and selling activity for Selecta Biosciences or view top insider-selling stocks.

SELB stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Morgan Stanley, BlackRock Inc., JPMorgan Chase & Co., Renaissance Technologies LLC, CM Management LLC, Cetera Advisors LLC, and Nuveen Asset Management LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Peter G Traber, Timothy A Springer, and Timothy C Barabe.
View insider buying and selling activity for Selecta Biosciences or or view top insider-buying stocks.

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SELB stock can currently be purchased for approximately $4.14.

Selecta Biosciences has a market capitalization of $447.24 million and generates $6.68 million in revenue each year. The company earns $-55,350,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

Selecta Biosciences employs 39 workers across the globe.

The official website for Selecta Biosciences is selectabio.com.

Selecta Biosciences is headquartered at 65 Grove Street, Watertown MA, 02472.

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]